Industry

Lupin recalls more than 2.5 million eye drops

Healio Optometry1d ago1 min read

Editor’s note: This is a developing news story. Please check back soon for updates.More than 2.5 million bottles of steroid eye drops aimed at relieving inflammation have been recalled, according to the FDA.Lupin Pharmaceuticals is recalling 2,530,182 bottles of prednisolone acetate ophthalmic solution 1%, including 5 mL, 10 mL and 15 mL bottles. The affected lots have expiration dates ranging from July 31, 2026, to March 31, 2028.The stated reason for the recall is “presence of foreign substance.” The recall, issued on June 4, is class II, meaning the products could cause

Read full article on Healio Optometry

AI Summary

Quick Take

Lupin Pharmaceuticals has initiated a Class II recall of more than 2.5 million bottles of Prednisolone Acetate Ophthalmic Solution 1% due to the presence of a foreign substance. The recall affects 5 mL, 10 mL, and 15 mL bottles with expiration dates ranging from July 2026 through March 2028.

Why It Matters

Prednisolone acetate is a cornerstone of post-operative care and the management of ocular inflammation, meaning a recall of this scale could significantly impact local supply chains and patient treatment plans. A Class II designation from the FDA suggests that while the risk of serious harm is low, the contaminated drops could cause temporary or medically reversible adverse health consequences. In a post-surgical context, the introduction of an unknown foreign substance into the eye is particularly concerning due to the risk of exacerbating inflammation or introducing infection.

Key Details

The recall involves a total of 2,530,182 bottles of Prednisolone Acetate Ophthalmic Solution 1%.
Affected products include three common dispensing sizes: 5 mL, 10 mL, and 15 mL bottles.
The FDA issued the Class II recall on June 4 following the discovery of a 'foreign substance' in the solution.
Affected lots carry expiration dates between July 31, 2026, and March 31, 2028.

Practice Implications

Clinicians should immediately audit their in-office inventories and sample closets to remove any Lupin-manufactured prednisolone. Patients currently using this medication for post-operative or uveitis management should be contacted to verify their lot numbers and, if necessary, transitioned to an alternative manufacturer to ensure continuity of care without risk of contamination.

Who's Affected

OphthalmologistsOptometristsPractice OwnersSurgical CentersPharmacists

What's Next

As this is a developing story, providers should watch for a comprehensive list of specific lot numbers from the FDA to assist in identifying affected bottles. Further updates may also clarify the nature of the foreign substance and the expected timeline for replacement stock to reach the market.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.